Mabylon

Executive Summary

Mabylon is a Swiss private biotechnology company founded in 2015 and headquartered in Zurich, focusing on the discovery and development of novel antibodies and biologics. The company operates at the preclinical to Phase 1 stage, with limited public disclosure of its technology platform or pipeline. While the biotherapeutic antibody space is competitive, Mabylon's early-stage positioning and lack of transparency make it challenging to assess. Nonetheless, the company may leverage its Swiss base for innovation and partnerships. Further information is needed to evaluate its potential.

Upcoming Catalysts (preview)

• Q3 2026Initiation of first-in-human Phase 1 trial for lead candidate40% success
• Q2 2026Announcement of Series A financing round50% success
• Q4 2026Disclosure of preclinical data or pipeline details30% success